Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $3.2 million.

  • Harvard Bioscience's Current Deferred Revenue fell 1415.02% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 1415.02%. This contributed to the annual value of $3.8 million for FY2024, which is 1557.23% down from last year.
  • Harvard Bioscience's Current Deferred Revenue amounted to $3.2 million in Q3 2025, which was down 1415.02% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Current Deferred Revenue ranged from a high of $4.5 million in Q4 2023 and a low of $3.2 million during Q3 2025
  • Moreover, its 5-year median value for Current Deferred Revenue was $3.7 million (2025), whereas its average is $3.8 million.
  • As far as peak fluctuations go, Harvard Bioscience's Current Deferred Revenue plummeted by 2100.33% in 2022, and later skyrocketed by 3376.85% in 2023.
  • Quarter analysis of 5 years shows Harvard Bioscience's Current Deferred Revenue stood at $4.3 million in 2021, then fell by 21.0% to $3.4 million in 2022, then soared by 33.77% to $4.5 million in 2023, then fell by 15.57% to $3.8 million in 2024, then decreased by 16.79% to $3.2 million in 2025.
  • Its Current Deferred Revenue stands at $3.2 million for Q3 2025, versus $3.4 million for Q2 2025 and $3.7 million for Q1 2025.